---
title: Faster and more targeted antibiotic diagnosis with investment in Shanx
date: 2026-01-07T09:19:00+01:00
author: Bram van den Hoogen
canonical_url: "https://www.bom.nl/en/articles/snellere-en-gerichtere-antibiotische-diagnose-met-investering-in-shanx"
section: News
---
#  Faster and more targeted antibiotic diagnosis with investment in Shanx 

 January 7, 2026 

 

 ShanX Medtech, an Eindhoven-based medtech start-up developing groundbreaking diagnostic technology for quickly determining the appropriate antibiotic treatment, has raised a total of €15 million in a seed round. Investors include Borski Fund, NextGen Ventures, CbusineZ – an independent investment fund closely linked to health insurer CZ –, Brabant Development Agency (BOM), Invest-NL, and a prominent strategic angel investor. This funding is in addition to the recently awarded European Commission tender of 8.85 million euros. 

 

 

 

 

 

   ![Untitled 116](https://d3d5gk1jdgmand.cloudfront.net/resized/_900x600_crop_center-center_none_ns/untitled-116.webp)  

   

 

 

  

 

Shanx focuses on one of the most urgent challenges in global healthcare: the increasing threat of antimicrobial resistance (AMR). The funding is used to expedite the completion of development, clinical validation, regulatory approval, and commercial launch of the SXM diagnostics platform. The platform is already receiving a lot of interest from healthcare institutions and commercial partners.

ShanX Medtech is a gamechanger in infectious care with ultra-rapid antimicrobial susceptibility tests (AST). By using innovative chemistry, SXM delivers comprehensive results within an hour. This is a breakthrough compared to current methods, which require trained personnel and take days. By enabling faster, evidence-based treatments, the platform has the potential to improve patient care, reduce healthcare costs, limit the spread of AMR, and strengthen pandemic preparedness.

 

 > Antimicrobial resistance represents one of the most critical unmet needs in global healthcare, with few effective solutions available today. ShanX Medtech introduces a highly innovative technology that contributes preventively to global health. As an early-stage investor, BOM is proud to take this next step alongside such a pioneering company.

###### Paul Vernooij

Investment Manager at the Brabant Development Agency (BOM)

 

 

 

 

 

 

 

## Learn more

   ![Paul Vernooij 25](https://d3d5gk1jdgmand.cloudfront.net/resized/employees/_500x500_crop_center-center_none_ns/130370/Paul-Vernooij-25.webp)  

  

### Paul Vernooij

Senior Investment Manager

  

- [  Phone ](tel:+31646996022)
- [  Email ](mailto:pvernooij@bom.nl)
- [  Chat via Teams ](https://teams.microsoft.com/l/chat/0/0?users=pvernooij@bom.nl)
 
 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

“We founded ShanX Medtech because of a single patient story, one that revealed how much is at stake when diagnostic results arrive too late,” said Dr. Sophia E. Shanko, Founder and CEO of ShanX Medtech. “Our vision is to equip every clinician with the ability to act decisively, guided by diagnostic evidence in real-time. This funding brings us significantly closer to delivering ultra-rapid AST directly to both laboratory and point-of-care environments; faster, simpler, and more accessible than ever before.”

**About ShanX Medtech**  
ShanX Medtech develops innovative In-Vitro Diagnostics (IVD) solutions that enable ultra-fast and accessible antimicrobial susceptibility testing to combat antimicrobial resistance (AMR) globally and improve public health. ShanX is located at the High Tech Campus in Eindhoven. With more than 350 MedTech companies, the campus is responsible for 90% of the Dutch MedTech patents. The ecosystem in Eindhoven combines top research, advanced manufacturing, and entrepreneurship to accelerate healthcare solutions from concept to market.